REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.03.22 | 07:00 | Permanent Information Releases / General Company News

puce Novartis plans for Alcon spin-off on April 9, 2019 - HTML (w)

2019.03.18 | 07:15 | Permanent Information Releases / General Company News

puce Alcon Announces Acquisition of PowerVision, Inc. - HTML (w)

2019.03.14 | 17:30 | Permanent Information Releases / General Company News

puce Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy - HTML (w)

2019.03.14 | 07:15 | Permanent Information Releases / Appointments

puce Novartis announces change in Sandoz leadership - HTML (w)

2019.03.11 | 00:36 | Permanent Information Releases / General Company News

puce Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW - HTML (w)

2019.03.05 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* - HTML (w)

2019.03.04 | 07:15 | Permanent Information Releases / General Company News

puce Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China - HTML (w)

2019.02.28 | 13:50 | Annual General Meeting / Reports

puce Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting - HTML (w)

2019.02.28 | 13:50 | Annual General Meeting / Reports

puce Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut - HTML (w)

2019.02.28 | 13:50 | Annual General Meeting / Reports

puce Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale - HTML (w)

2019.02.25 | 23:55 | Permanent Information Releases / General Company News

puce Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off - HTML (w)

2019.02.25 | 07:15 | Permanent Information Releases / General Company News

puce Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) - HTML (w)

2019.02.13 | 22:23 | Permanent Information Releases / General Company News

puce Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease - HTML (w)

2019.01.30 | 07:00 | Permanent Information Releases / General Company News

puce En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise - HTML (w)

2019.01.30 | 07:00 | Permanent Information Releases / General Company News

puce Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1179